Using Glycopolymers to Study the Role of Galectin-3 in Cancer Progressions for Applications in Ovarian Cancer

Samantha Hansen, Hazal Evans, and Dr. Mary Cloninger Department of Chemistry and Biochemistry, Montana State University 103 Chemistry and Biochemistry Building Bozeman, MT 59717

Treating ovarian cancers has become increasingly more difficult, as many ovarian cancer cell lines appear to have gained resistance to the platinum-based chemotherapeutic agents that are the current standard of care. Galectin-3 is a protein with strong implications in the progression of cancer, including tumor growth, angiogenesis, and metastasis. Expression of this protein in ovarian cancer has been correlated with the grade, clinical stage, recurrence, and platinum resistance. We intend to use lactose-functionalized PAMAM glycopolymers to bind and inhibit galectin-3, ultimately restoring the function of these chemotherapeutic agents. Our goal is to develop nontoxic glycopolymers which divert the protein from its targets of action, thereby overcoming resistance to platinum-based chemotherapeutic agents in treatment of ovarian cancer. Toward this aim, we are studying several cancer cell lines with varying amounts of endogenous galectin-3. Cancer cellular proliferation, cytotoxicity, and cellular viability in the presence of glycodendrimers, and chemotherapeutic agents are being studied. These assays will be performed using only the endogenous galectin-3 as well as with added galectin-3 to assess the impact of galectin-3 on processes involved in cancer progression. Understanding the role of galectin-3 as it functions in cancer cells during current standard-of-care therapies has the potential to dramatically improve the treatment of ovarian cancer.

Additional Abstract Information

Presenter: Samantha Hansen

Institution: Montana State University Bozeman

Type: Poster

Subject: Biochemistry

Status: Approved

Time and Location

Session: Poster 1
Date/Time: Mon 1:30pm-2:30pm
Session Number: 2132